Google searches for the weight loss drug Mounjaro soared by 74% across the UK on 23 June 2025, coinciding with the start of NHS prescriptions through general practitioners in England. The antidiabetic medication, known as tirzepatide and manufactured by Eli Lilly, is primarily used to manage blood sugar levels but has gained attention for its weight loss benefits. It helps users lose up to 20% of their body weight by reducing appetite.
Google Trends data analysed by QR Code Generator highlights a national spike in interest within 24 hours of the rollout. Regional hotspots included Widnes, Hartlepool, Arley, Dudley, and Sunderland. This surge reflects growing public curiosity about the drug’s availability and strict eligibility rules as GPs prescribe Mounjaro for the first time, following its previous restriction to specialist weight management services.
Around 220,000 people with the greatest clinical need are expected to access the drug over the next three years. In the first year, eligible patients must have a body mass index above 40 or above 37.5 for those from Black, Asian, or minority ethnic backgrounds. They must also have at least four obesity-related conditions such as type 2 diabetes, high blood pressure, heart disease, or obstructive sleep apnoea.
Searches for “Mounjaro criteria NHS” surged by 250% over the past week. “Mounjaro NHS Scotland” rose by 130% as people explored access in regions where health boards control availability and few patients receive weight loss medication on the NHS. Searches for “what’s my BMI” also rose by 50%, suggesting many are checking their eligibility.
Marc Porcar, CEO of QR Code Generator Pro S.L., commented on the findings. He said the NHS rollout of Mounjaro prescriptions through GPs is a major step in managing diabetes and treating obesity in the UK. He warned that the launch may tempt those who do not meet the criteria or who are frustrated by long wait times to seek the drug from less reputable sources. He highlighted the risk of misuse without medical oversight, noting serious side effects if users are dishonest about their BMI or medical history. He added that scammers may offer fake prescriptions and called for clear public health messaging and strong regulation of the online marketplace to prevent exploitation.
Professor Kamila Hawthorne, chair of the Royal College of General Practitioners, said GPs recognise the potential benefits of weight loss drugs but have concerns about the rollout’s impact on workload and the need for training to manage these treatments safely. She emphasised that these drugs should not be seen as a silver bullet for weight loss.
Olivier Picard, chairman of the National Pharmacy Association, pointed out that the demand for weight loss jabs is rising sharply. He noted that more GPs have been directing patients back to pharmacies after initial inquiries to access treatments privately.
The NHS rollout includes wraparound care such as dietary and lifestyle support to help ensure sustainable outcomes for patients.
